Lv1
30 积分 2024-11-25 加入
Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myeloma
4天前
已完结
Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye
1个月前
已关闭
An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma
2个月前
已完结
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
5个月前
已完结
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
5个月前
已完结
SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors
7个月前
已完结
Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance
8个月前
已完结
PLK4 inhibitor plus bortezomib exhibits a synergistic effect on treating multiple myeloma via inactivating PI3K/AKT signaling
8个月前
已完结
BRMS1 suppresses the PI3K/AKT/mTOR pathway to regulate autophagy in multiple myeloma
8个月前
已完结
IGF-1 promotes multiple myeloma progression through PI3K/Akt-mediated epithelial-mesenchymal transition
8个月前
已完结
皖公网安备34019202002308
